Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • History
    • Our Leadership
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Multiple Myeloma
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • What is Gene Therapy?
    • Gene Therapy Techniques
    • Clinical Trials
    • Our Pipeline
  • Our Products
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Corporate Presentation
  • Our Value Model
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Jenn Snyder

    VP, Corporate Communications

    (617) 448-0281

    JSnyder@bluebirdbio.com

  • Catherine Falcetti

    Senior Director, Corporate Communications

    (339) 499-9436

    CFalcetti@bluebirdbio.com

Investor Contact

  • Elizabeth Pingpank

    Director, Corporate Communications

    (617) 914-8736

    EPingpank@bluebirdbio.com

Bank of America Merrill Lynch Health Care Conference 2019

  • Read more about Bank of America Merrill Lynch Health Care Conference 2019

bluebird bio Announces Investor Events in May

  • Read more about bluebird bio Announces Investor Events in May

bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress

  • Read more about bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress

Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine

  • Read more about Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine

bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer

  • Read more about bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer

Analyst Day

  • Read more about Analyst Day

bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype

  • Read more about bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype

bluebird bio Statement on European Regulatory Status of LentiGlobin™

  • Read more about bluebird bio Statement on European Regulatory Status of LentiGlobin™

bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina

  • Read more about bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina

Barclays Global Healthcare Conference

  • Read more about Barclays Global Healthcare Conference

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Quick Links

  • Patients & Advocacy
  • Investors & Media
  • Careers
  • Contact Us

CONTACT INFO

info@bluebirdbio.com

clinicaltrials@bluebirdbio.com

investor@bluebirdbio.com

medinfo@bluebirdbio.com

Live - Terms & Privacy

  • Terms of Service
  • Privacy Policy
  • Cookie Notice
  • Sitemap
© 2019 bluebird bio, Inc. All Rights Reserved. Corp-GBL-00011 05/19

Live - Social Links